Indoleamine 2,3-Dioxygenase as a Therapeutic Target for Alzheimer’s Disease and Geriatric Depression
Brain Sciences · 24.05.2023 · 13 (6) · 852
DOI: 10.3390/brainsci13060852 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Brain Sciences, online erschienen am 24.05.2023. Verfasst von Karl Savonije und 2 weiteren Autor:innen. Beteiligte Einrichtung: Krembil Research Institute, University Health Network, Toronto, ON M5T 0S8, Canada. Die Arbeit wurde bisher 29-mal zitiert (Crossref) und nennt 84 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Krembil Foundation, the Krembil Foundation, the Weston Foundation.
Themen: Depression, Demenz
Abstract (Originalsprache)
Neuroimmune-triggered neuroinflammation of the central nervous system is emerging as an important aetiopathogenic factor for multiple neurological disorders, including depression, dementia, Alzheimer’s disease, multiple sclerosis and others. Tryptophan metabolism via the kynurenic pathway, which is initiated by the indoleamine-2,3-dioxygenase (IDO-1) enzyme, is a key regulator of the neuroimmune system and its associated neuroinflammatory effects. As discussed in this review, targeting the production of immunopathic and potentially neurotoxic kynurenine metabolites by inhibitory downregulation of IDO-1 may prove a viable target against inflammation-induced neurological conditions, particularly depression and dementia.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Krembil Research Institute, University Health Network, Toronto, ON M5T 0S8, Canada.
- Departments of Chemistry and Medicine, University of Toronto, Toronto, ON M5S 3M2, Canada.
ORCID-Profile: Autumn Meek
Förderung
- Krembil Foundation
- the Krembil Foundation
- the Weston Foundation
- a Harrington Scholar-Innovator Award
Zitieren
APA
Savonije, K., Meek, A., & Weaver, D. F. (2023). Indoleamine 2,3-Dioxygenase as a Therapeutic Target for Alzheimer’s Disease and Geriatric Depression. Brain Sciences, 13(6), 852. https://doi.org/10.3390/brainsci13060852
Vancouver
Savonije K, Meek A, Weaver DF. Indoleamine 2,3-Dioxygenase as a Therapeutic Target for Alzheimer’s Disease and Geriatric Depression. Brain Sciences. 2023;13(6):852. doi:10.3390/brainsci13060852
BibTeX
@article{Savonije2023,
author = {Savonije, Karl and Meek, Autumn and Weaver, Donald F},
title = {Indoleamine 2,3-Dioxygenase as a Therapeutic Target for Alzheimer’s Disease and Geriatric Depression},
journal = {Brain Sciences},
year = {2023},
volume = {13},
number = {6},
pages = {852},
doi = {10.3390/brainsci13060852}
}
EUVIMED